首页> 外文期刊>Cardiology research and practice >Transcatheter versus Surgical Aortic Valve Replacement after Previous Cardiac Surgery: A Systematic Review and Meta-Analysis
【24h】

Transcatheter versus Surgical Aortic Valve Replacement after Previous Cardiac Surgery: A Systematic Review and Meta-Analysis

机译:先前心脏手术后经导管vs外科主动脉瓣置换术:系统评价和荟萃分析

获取原文
           

摘要

Aim. Aortic valve replacement (AVR) in patients with prior cardiac surgery might be challenging. Transcatheter aortic valve replacement (TAVR) offers a promising alternative in such patients. We therefore aimed at comparing the outcomes of patients with aortic valve diseases undergoing TAVR versus those undergoing surgical AVR (SAVR) after previous cardiac surgery. Methods and Results. MEDLINE, EMBASE, and the Cochrane Central Register were searched. Seven relevant studies were identified, published between 01/2011 and 12/2015, enrolling a total of 1148 patients with prior cardiac surgery (97.6% prior CABG) 49.2% underwent TAVR, whereas 50.8% underwent SAVR. Incidence of stroke (3.8 versus 7.9%, ) and major bleeding (8.3 versus 15.3%, ) was significantly lower in the TAVR group. Incidence of mild/severe paravalvular leakage (14.4/10.9 versus 0%, ) and pacemaker implantation (11.3 versus 3.9%, ) was significantly higher in the TAVR group. There were no significant differences in the incidence of acute kidney injury (9.7 versus 8.7%, ), major adverse cardiovascular events (8.7 versus 12.3%, ), 30-day mortality (5.1 versus 5.5%, ), or 1-year mortality (11.6 versus 11.8%, ) between the TAVR and SAVR group. Conclusions. TAVR as a redo procedure offers a safe alternative for patients presenting with aortic valve diseases after previous cardiac surgery especially those with prior CABG.
机译:目标。在进行过心脏手术的患者中主动脉瓣置换术(AVR)可能具有挑战性。经导管主动脉瓣置换术(TAVR)为此类患者提供了有希望的替代方法。因此,我们旨在比较接受过TAVR的主动脉瓣疾病患者与先前进行心脏手术后接受手术AVR(SAVR)的患者的结局。方法和结果。搜索MEDLINE,EMBASE和Cochrane中央注册簿。确定了7项相关研究,发表于01/2011至12/2015之间,共有1148例接受过心脏手术的患者(97.6%接受CABG之前)接受TAVR的患者占49.2%,而接受SAVR的患者占50.8%。 TAVR组中风发生率(3.8%vs. 7.9%)和大出血发生率(8.3%vs 15.3%)显着降低。 TAVR组轻度/重度瓣周漏发生率(14.4 / 10.9对0%,)和起搏器植入(11.3对3.9%,)。急性肾损伤的发生率(9.7对8.7%),主要的不良心血管事件(8.7对12.3%),30天死亡率(5.1对5.5%)或1年死亡率(均无显着差异)。 TAVR和SAVR组之间的比例分别为11.6%和11.8%。结论。 TAVR作为一种重做程序,为先前心脏手术后出现主动脉瓣疾病的患者,尤其是先前CABG的患者提供了一种安全的选择。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号